{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:02:53Z","timestamp":1793037773126,"version":"4.5.0"},"reference-count":142,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite advancements in health systems and intensive care unit (ICU) care, along with the introduction of novel antibiotics and microbiologic techniques, mortality rates in severe community-acquired pneumonia (sCAP) patients have not shown significant improvement. Delayed admission to the ICU is a major risk factor for higher mortality. Apart from choosing the appropriate site of care, prompt and appropriate antibiotic therapy significantly affects the prognosis of sCAP. Treatment regimens involving ceftaroline or ceftobiprole are currently considered the best options for managing patients with sCAP. Additionally, several other molecules, such as delafloxacin, lefamulin, and omadacycline, hold promise as therapeutic strategies for sCAP. This review aims to provide a comprehensive summary of the key challenges in managing adults with severe CAP, focusing on essential aspects related to antibiotic treatment and investigating potential strategies to enhance clinical outcomes in sCAP patients.<\/jats:p>","DOI":"10.1055\/s-0043-1778641","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T23:47:01Z","timestamp":1706831221000},"page":"187-199","source":"Crossref","is-referenced-by-count":9,"title":["Antibiotic Strategies for Severe Community-Acquired Pneumonia"],"prefix":"10.1055","volume":"45","author":[{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Policlinico San Martino Hospital, IRCCS, Genoa, Italy"},{"name":"Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele R.","family":"Giacobbe","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Policlinico San Martino Hospital, IRCCS, Genoa, Italy"},{"name":"Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Magnasco","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Policlinico San Martino Hospital, IRCCS, Genoa, Italy"},{"name":"Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Fantin","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Policlinico San Martino Hospital, IRCCS, Genoa, Italy"},{"name":"Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Castaldo","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0149-2918(98)80144-6","article-title":"The cost of treating community-acquired pneumonia","volume":"20","author":"M S Niederman","year":"1998","journal-title":"Clin Ther"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00134-019-05519-y","article-title":"Challenges in severe community-acquired pneumonia: a point-of-view review","volume":"45","author":"A Torres","year":"2019","journal-title":"Intensive Care Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"L A Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.chest.2020.03.051","article-title":"The burden of community-acquired pneumonia requiring admission to ICU in the United States","volume":"158","author":"R Cavallazzi","year":"2020","journal-title":"Chest"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"2200735","DOI":"10.1183\/13993003.00735-2022","article-title":"ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia","volume":"61","author":"I Martin-Loeches","year":"2023","journal-title":"Eur Respir J"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1378\/chest.09-1547","article-title":"Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality","volume":"137","author":"M I Restrepo","year":"2010","journal-title":"Chest"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jcrc.2017.08.048","article-title":"Impact of antibiotic therapy in severe community-acquired pneumonia: data from the INFAUCI study","volume":"43","author":"J M Pereira","year":"2018","journal-title":"J Crit Care"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00134-011-2261-x","article-title":"Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis","volume":"37","author":"J D Chalmers","year":"2011","journal-title":"Intensive Care Med"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/thoraxjnl-2014-206744","article-title":"Community-acquired pneumonia as medical emergency: predictors of early deterioration","volume":"70","author":"M Kolditz","year":"2015","journal-title":"Thorax"},{"issue":"16","key":"ref10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/BF01721926","article-title":"Effect of low dose of cimetidine on gastric potentials difference and acetylsalicylic acid-induced change","volume":"59","author":"S Massarrat","year":"1981","journal-title":"Klin Wochenschr"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1086\/589754","article-title":"SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia","volume":"47","author":"P G Charles","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/CCM.0b013e318194b021","article-title":"PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia","volume":"37","author":"J Rello","year":"2009","journal-title":"Crit Care Med"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7861\/clinmedicine.12-6-501","article-title":"NEWSDIG: the National Early Warning Score development and implementation group","volume":"12","author":"M Jones","year":"2012","journal-title":"Clin Med (Lond)"},{"issue":"05","key":"ref14","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1378\/chest.08-0842","article-title":"Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience","volume":"134","author":"M D Zilberberg","year":"2008","journal-title":"Chest"},{"issue":"16","key":"ref15","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/archinternmed.2009.259","article-title":"Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules","volume":"169","author":"C McCabe","year":"2009","journal-title":"Arch Intern Med"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1055\/s-0029-1202934","article-title":"Early and late treatment failure in community-acquired pneumonia","volume":"30","author":"C Garcia-Vidal","year":"2009","journal-title":"Semin Respir Crit Care Med"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"J P Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/CCM.0000000000004267","article-title":"Effect of antibiotic discontinuation strategies on mortality and infectious complications in critically ill septic patients: a meta-analysis and trial sequential analysis","volume":"48","author":"N Arulkumaran","year":"2020","journal-title":"Crit Care Med"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1164\/rccm.200708-1238OC","article-title":"Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial","volume":"177","author":"V Nobre","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"9713","key":"ref20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","article-title":"Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial","volume":"375","author":"L Bouadma","year":"2010","journal-title":"Lancet"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","article-title":"Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial","volume":"16","author":"E de Jong","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.88","article-title":"Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial","volume":"313","author":"A Torres","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"ref23","first-page":"CD007720","article-title":"Corticosteroids for pneumonia","volume":"12","author":"A Stern","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/cid\/cix801","article-title":"Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis","volume":"66","author":"M Briel","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"21","key":"ref25","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","article-title":"Hydrocortisone in severe community-acquired pneumonia","volume":"388","author":"P F Dequin","year":"2023","journal-title":"N Engl J Med"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1164\/rccm.200406-808OC","article-title":"Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study","volume":"171","author":"M Confalonieri","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10096-012-1802-8","article-title":"Incidence of respiratory viruses in patients with community-acquired pneumonia admitted to the intensive care unit: results from the severe influenza pneumonia surveillance (SIPS) project","volume":"32","author":"T Wiemken","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/bjaed\/mkv052","article-title":"Severe community-acquired pneumonia","volume":"16","author":"A J Morgan","year":"2016","journal-title":"BJA Educ"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1440-1843.2008.01371.x","article-title":"Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli","volume":"14","author":"M Falguera","year":"2009","journal-title":"Respirology"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1186\/s12879-018-3565-z","article-title":"Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective","volume":"18","author":"A Gramegna","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"e0191721","DOI":"10.1371\/journal.pone.0191721","article-title":"Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients","volume":"13","author":"M Ferrer","year":"2018","journal-title":"PLoS One"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"S Jain","year":"2015","journal-title":"N Engl J Med"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/thx.2010.143982","article-title":"Microbial aetiology of community-acquired pneumonia and its relation to severity","volume":"66","author":"C Cill\u00f3niz","year":"2011","journal-title":"Thorax"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00134-020-06323-9","article-title":"Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study","volume":"47","author":"A Rouz\u00e9","year":"2021","journal-title":"Intensive Care Med"},{"issue":"03","key":"ref35","first-page":"E163","article-title":"The burden of severe cases of Influenza disease: the Friuli Venezia Giulia Region experience","volume":"60","author":"M Bassetti","year":"2019","journal-title":"J Prev Med Hyg"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/thoraxjnl-2013-203384","article-title":"Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective","volume":"68","author":"S Aliberti","year":"2013","journal-title":"Thorax"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/S1473-3099(16)30267-5","article-title":"Global initiative for methicillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study","volume":"16","author":"S Aliberti","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/microorganisms7020049","article-title":"PES pathogens in severe community-acquired pneumonia","volume":"7","author":"C Cill\u00f3niz","year":"2019","journal-title":"Microorganisms"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"1701190","DOI":"10.1183\/13993003.01190-2017","article-title":"Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients","volume":"52","author":"M I Restrepo","year":"2018","journal-title":"Eur Respir J"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/resp.13663","article-title":"Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia","volume":"25","author":"D Villafuerte","year":"2020","journal-title":"Respirology"},{"issue":"10","key":"ref41","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/cid\/cix549","article-title":"Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus","volume":"65","author":"D M Musher","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12890-019-0944-1","article-title":"Severe community-acquired pneumonia in general medical wards: outcomes and impact of initial antibiotic selection","volume":"19","author":"P Wongsurakiat","year":"2019","journal-title":"BMC Pulm Med"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jinf.2013.03.003","article-title":"Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study","volume":"67","author":"D M Musher","year":"2013","journal-title":"J Infect"},{"issue":"07","key":"ref44","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/civ1214","article-title":"Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia","volume":"62","author":"N J Gadsby","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"07","key":"ref45","doi-asserted-by":"crossref","first-page":"e00128-20","DOI":"10.1128\/JCM.00128-20","article-title":"Multicenter evaluation of the BioFire FilmArray pneumonia\/pneumonia plus panel for detection and quantification of agents of lower respiratory tract infection","volume":"58","author":"C N Murphy","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"11","key":"ref46","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1097\/CCM.0000000000001249","article-title":"Rapid diagnosis of infection in the critically ill, a multicenter study of molecular detection in bloodstream infections, pneumonia, and sterile site infections","volume":"43","author":"J L Vincent","year":"2015","journal-title":"Crit Care Med"},{"issue":"02","key":"ref47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1513\/AnnalsATS.201407-305OC","article-title":"Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia","volume":"12","author":"E Prina","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"e0119528","DOI":"10.1371\/journal.pone.0119528","article-title":"Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia","volume":"10","author":"M Falcone","year":"2015","journal-title":"PLoS One"},{"issue":"02","key":"ref49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QCO.0000000000000254","article-title":"Empiric antibiotic selection and risk prediction of drug-resistant pathogens in community-onset pneumonia","volume":"29","author":"B J Webb","year":"2016","journal-title":"Curr Opin Infect Dis"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jfma.2015.03.009","article-title":"Selection of empirical antibiotics for health care-associated pneumonia via integration of pneumonia severity index and risk factors of drug-resistant pathogens","volume":"115","author":"P H Wang","year":"2016","journal-title":"J Formos Med Assoc"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/cir813","article-title":"Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department","volume":"54","author":"A F Shorr","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"04","key":"ref52","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cir840","article-title":"Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia","volume":"54","author":"S Aliberti","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jfma.2011.09.028","article-title":"Antimicrobial drug-resistant microbes associated with hospitalized community-acquired and healthcare-associated pneumonia: a multi-center study in Taiwan","volume":"112","author":"C L Wu","year":"2013","journal-title":"J Formos Med Assoc"},{"issue":"04","key":"ref54","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0012-3692(15)50958-6","article-title":"Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia","volume":"130","author":"A F Shorr","year":"2006","journal-title":"Chest"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09031936.00188710","article-title":"Initial management of pneumonia and sepsis: factors associated with improved outcome","volume":"39","author":"R Men\u00e9ndez","year":"2012","journal-title":"Eur Respir J"},{"issue":"02","key":"ref57","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","article-title":"Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"42","author":"W I Sligl","year":"2014","journal-title":"Crit Care Med"},{"issue":"02","key":"ref58","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1378\/chest.128.2.940","article-title":"The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia","volume":"128","author":"K Weiss","year":"2005","journal-title":"Chest"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1164\/rccm.200311-1578OC","article-title":"Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia","volume":"170","author":"L M Baddour","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"ref60","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.chest.2018.11.006","article-title":"Effect of combined \u03b2-lactam\/macrolide therapy on mortality according to the microbial etiology and inflammatory status of patients with community-acquired pneumonia","volume":"155","author":"A Ceccato","year":"2019","journal-title":"Chest"},{"issue":"11","key":"ref61","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1128\/AAC.00006-07","article-title":"Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia","volume":"51","author":"T P Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"02","key":"ref62","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1378\/chest.06-1426","article-title":"Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones","volume":"131","author":"M L Metersky","year":"2007","journal-title":"Chest"},{"issue":"04","key":"ref63","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jinf.2018.01.003","article-title":"Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: a propensity score analysis","volume":"76","author":"C De la Calle","year":"2018","journal-title":"J Infect"},{"issue":"02","key":"ref64","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/jac\/dkl479","article-title":"Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae","volume":"59","author":"R Anderson","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"04","key":"ref65","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cmi.2016.12.002","article-title":"Fluoroquinolones or macrolides in combination with \u03b2-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis","volume":"23","author":"K Z Vardakas","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"04","key":"ref66","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","article-title":"Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia","volume":"36","author":"I Martin-Loeches","year":"2010","journal-title":"Intensive Care Med"},{"issue":"06","key":"ref67","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1378\/chest.125.6.2135","article-title":"Levofloxacin efficacy in the treatment of community-acquired legionellosis","volume":"125","author":"V L Yu","year":"2004","journal-title":"Chest"},{"issue":"06","key":"ref68","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1086\/428059","article-title":"Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy","volume":"40","author":"A Mykietiuk","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"06","key":"ref69","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/428049","article-title":"Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides","volume":"40","author":"R M Bl\u00e1zquez Garrido","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"09","key":"ref70","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1093\/jac\/dku159","article-title":"Quinolones versus macrolides in the treatment of legionellosis: a systematic review and meta-analysis","volume":"69","author":"C Burdet","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1378\/chest.128.3.1401","article-title":"Fluoroquinolones vs macrolides in the treatment of Legionnaires disease","volume":"128","author":"M Sabri\u00e0","year":"2005","journal-title":"Chest"},{"issue":"05","key":"ref72","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/jac\/dkx007","article-title":"Antimicrobial strategy for severe community-acquired legionnaires' disease: a multicentre retrospective observational study","volume":"72","author":"J Cecchini","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"04","key":"ref73","doi-asserted-by":"crossref","first-page":"ofx184","DOI":"10.1093\/ofid\/ofx184","article-title":"Tigecycline as a second-line agent for Legionnaires' disease in severely ill patients","volume":"4","author":"D Slawek","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"04","key":"ref74","first-page":"e4577","article-title":"Successful treatment of legionnaires' disease with tigecycline in an immunocompromised man with a Legion of antibiotic allergies","volume":"11","author":"M Arget","year":"2019","journal-title":"Cureus"},{"issue":"05","key":"ref75","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/jac\/38.5.865","article-title":"Penetration of vancomycin into human lung tissue","volume":"38","author":"M Cruciani","year":"1996","journal-title":"J Antimicrob Chemother"},{"issue":"06","key":"ref76","doi-asserted-by":"crossref","first-page":"e99044","DOI":"10.1371\/journal.pone.0099044","article-title":"Guidelines for therapeutic drug monitoring of vancomycin: a systematic review","volume":"9","author":"Z K Ye","year":"2014","journal-title":"PLoS One"},{"issue":"03","key":"ref77","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/14656566.2021.2010706","article-title":"Current pharmacotherapy for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia","volume":"23","author":"M Bassetti","year":"2022","journal-title":"Expert Opin Pharmacother"},{"issue":"03","key":"ref78","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.1111\/1469-0691.12022","article-title":"Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia\u2013results of a prospective observational study","volume":"19","author":"N Sicot","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"04","key":"ref79","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1378\/chest.128.4.2732","article-title":"Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production","volume":"128","author":"S T Micek","year":"2005","journal-title":"Chest"},{"issue":"06","key":"ref80","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/00006454-200206000-00010","article-title":"Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children","volume":"21","author":"A L Frank","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"01","key":"ref81","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/jac\/dkp377","article-title":"Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?","volume":"65","author":"H M Nguyen","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"01","key":"ref82","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s12879-017-2584-5","article-title":"Inducible clindamycin and methicillin resistant Staphylococcus aureus in a tertiary care hospital, Kathmandu, Nepal","volume":"17","author":"R P Adhikari","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"02","key":"ref83","first-page":"82","article-title":"Inducible clindamycin resistance in Staphylococcus aureus isolates recovered from Mashhad, Iran","volume":"4","author":"N Seifi","year":"2012","journal-title":"Iran J Microbiol"},{"issue":"06","key":"ref84","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkg262","article-title":"Intrapulmonary penetration of linezolid","volume":"51","author":"D Honeybourne","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"ref85","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/0036554021000026933","article-title":"Linezolid versus ceftriaxone\/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia","volume":"34","author":"G S San Pedro","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jgar.2020.12.009","article-title":"Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus","volume":"24","author":"H Kato","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"issue":"04","key":"ref87","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1592\/phco.30.4.375","article-title":"Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens","volume":"30","author":"M E Steed","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"11","key":"ref88","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1345\/aph.1Q225","article-title":"Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"45","author":"M R Jorgenson","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"03","key":"ref89","doi-asserted-by":"crossref","first-page":"114843","DOI":"10.1016\/j.diagmicrobio.2019.05.015","article-title":"Activity of ceftaroline against pathogens associated with community-acquired pneumonia collected as part of the AWARE surveillance program, 2015-2016","volume":"95","author":"I G Bae","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"10","key":"ref90","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1128\/AAC.02755-15","article-title":"Penetration of ceftaroline into the epithelial lining fluid of healthy adult subjects","volume":"60","author":"T A Riccobene","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"ref91","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1128\/AAC.03742-14","article-title":"In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus","volume":"58","author":"S H MacVane","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"S 03","key":"ref93","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"T M File Jr","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"S 03","key":"ref94","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"D E Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"ref95","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"T M File Jr","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref96","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial","volume":"15","author":"N S Zhong","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"ref97","volume-title":"CAPTURE study experience in patients with community acquired pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA) and treatment with ceftaroline presented at: ECCMID;","author":"A UG Jandourek","year":"2013"},{"issue":"04","key":"ref98","doi-asserted-by":"crossref","first-page":"105921","DOI":"10.1016\/j.ijantimicag.2020.105921","article-title":"Ceftaroline for severe community-acquired pneumonia: a real-world two-centre experience in Italy and Spain","volume":"55","author":"M Bassetti","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"02","key":"ref99","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijantimicag.2019.05.023","article-title":"Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis","volume":"54","author":"K Eljaaly","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"02","key":"ref100","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13696998.2019.1688819","article-title":"Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain","volume":"23","author":"A Torres","year":"2020","journal-title":"J Med Econ"},{"issue":"04","key":"ref101","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/14728214.2019.1685494","article-title":"Emerging antibiotics for community-acquired pneumonia","volume":"24","author":"A Liapikou","year":"2019","journal-title":"Expert Opin Emerg Drugs"},{"issue":"09","key":"ref102","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/14787210.2019.1667229","article-title":"Ceftobiprole: drug evaluation and place in therapy","volume":"17","author":"D R Giacobbe","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"01","key":"ref103","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diagmicrobio.2008.02.008","article-title":"Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006)","volume":"61","author":"T R Fritsche","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"12","key":"ref104","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s40262-016-0418-z","article-title":"Pharmacokinetics and dosing of ceftobiprole medocaril for the treatment of hospital- and community-acquired pneumonia in different patient populations","volume":"55","author":"A Torres","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"03","key":"ref105","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"S C Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"01","key":"ref106","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12879-019-3820-y","article-title":"Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials","volume":"19","author":"T WL Scheeren","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"02","key":"ref107","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.1186\/cc13812","article-title":"Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort","volume":"18","author":"A P Walden","year":"2014","journal-title":"Crit Care"},{"issue":"18","key":"ref108","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s40265-016-0667-z","article-title":"Solithromycin: a novel fluoroketolide for the treatment of community-acquired bacterial pneumonia","volume":"76","author":"G G Zhanel","year":"2016","journal-title":"Drugs"},{"issue":"04","key":"ref109","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1128\/AAC.02316-12","article-title":"Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae","volume":"57","author":"W Rodgers","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"04","key":"ref110","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","article-title":"Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)","volume":"16","author":"C M Barrera","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"08","key":"ref111","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/cid\/ciw490","article-title":"SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia","volume":"63","author":"T M File Jr","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"06","key":"ref113","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical review of delafloxacin: a novel anionic fluoroquinolone","volume":"73","author":"B T Mogle","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"03","key":"ref114","doi-asserted-by":"crossref","first-page":"e01949-19","DOI":"10.1128\/AAC.01949-19","article-title":"Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): microbiology results from the delafloxacin phase 3 CABP trial","volume":"64","author":"S McCurdy","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"04","key":"ref115","doi-asserted-by":"crossref","first-page":"e02609-16","DOI":"10.1128\/AAC.02609-16","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","volume":"61","author":"M A Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"05","key":"ref116","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijantimicag.2016.08.012","article-title":"Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens","volume":"48","author":"A K Thabit","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"ref119","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s40261-020-00953-z","article-title":"Community-acquired bacterial pneumonia-changing epidemiology, resistance patterns, and newer antibiotics: spotlight on delafloxacin","volume":"40","author":"R Sharma","year":"2020","journal-title":"Clin Drug Investig"},{"issue":"06","key":"ref120","first-page":"e374","article-title":"Nemonoxacin has potent activity against gram-positive, but not gram-negative clinical isolates","volume":"166","author":"Z X Li","year":"2015","journal-title":"Clin Ter"},{"key":"ref121","first-page":"765","article-title":"Review of nemonoxacin with special focus on clinical development","volume":"8","author":"X Qin","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"02","key":"ref122","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1517\/14656566.2015.978288","article-title":"The potential role of nemonoxacin for treatment of common infections","volume":"16","author":"C H Huang","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"ref124","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/00498254.2020.1756007","article-title":"Assessment of in vitro inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes","volume":"50","author":"R Chavan","year":"2020","journal-title":"Xenobiotica"},{"issue":"03","key":"ref125","first-page":"455","article-title":"Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trials","volume":"67","author":"I Karpiuk","year":"2013","journal-title":"Przegl Epidemiol"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/IDR.S193233","article-title":"The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials","volume":"12","author":"S P Chang","year":"2019","journal-title":"Infect Drug Resist"},{"issue":"11","key":"ref127","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1128\/AAC.01536-15","article-title":"Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline","volume":"59","author":"L Honeyman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"03","key":"ref128","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1128\/AAC.01066-13","article-title":"Mechanism of action of the novel aminomethylcycline antibiotic omadacycline","volume":"58","author":"M P Draper","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"05","key":"ref129","doi-asserted-by":"crossref","first-page":"e02488-19","DOI":"10.1128\/AAC.02488-19","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018","volume":"64","author":"M A Pfaller","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"03","key":"ref130","doi-asserted-by":"crossref","first-page":"e02411-16","DOI":"10.1128\/AAC.02411-16","article-title":"Activities of omadacycline and comparator agents against Staphylococcus aureus isolates from a surveillance program conducted in North America and Europe","volume":"61","author":"M A Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"09","key":"ref131","doi-asserted-by":"crossref","first-page":"e01135-17","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"M H Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"08","key":"ref132","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","article-title":"Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline","volume":"47","author":"J Flarakos","year":"2017","journal-title":"Xenobiotica"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijid.2021.01.032","article-title":"Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia","volume":"104","author":"A Torres","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"05","key":"ref135","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/jac\/dks001","article-title":"Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)","volume":"67","author":"H S Sader","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"09","key":"ref136","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/phar.2166","article-title":"Lefamulin: review of a promising novel pleuromutilin antibiotic","volume":"38","author":"M P Veve","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"09","key":"ref137","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11908-020-00732-z","article-title":"Clinical utility of lefamulin: if not now, when?","volume":"22","author":"N J Mercuro","year":"2020","journal-title":"Curr Infect Dis Rep"},{"issue":"11","key":"ref139","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/cid\/ciz090","article-title":"Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) trial","volume":"69","author":"T M File","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"17","key":"ref140","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.2019.15468","article-title":"Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial","volume":"322","author":"E Alexander","year":"2019","journal-title":"JAMA"},{"issue":"03","key":"ref141","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jac\/dkl304","article-title":"In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent","volume":"58","author":"A R Kwon","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"ref142","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1093\/jac\/dkt217","article-title":"A phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia","volume":"68","author":"P S Covington","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"07","key":"ref143","doi-asserted-by":"crossref","first-page":"e00468-17","DOI":"10.1128\/AAC.00468-17","article-title":"Gepotidacin (GSK2140944) in vitro activity against gram-positive and gram-negative bacteria","volume":"61","author":"R K Flamm","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"09","key":"ref144","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1128\/AAC.48.9.3338-3342.2004","article-title":"In vitro activity of the new quinolone WCK 771 against staphylococci","volume":"48","author":"M R Jacobs","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref145","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/COPD.S90948","article-title":"Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, phase III, non-inferiority trial","volume":"10","author":"C K Rhee","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"01","key":"ref146","doi-asserted-by":"crossref","first-page":"e00004-17","DOI":"10.1128\/mSphere.00004-17","article-title":"Fluorocycline TP-271 is potent against complicated community-acquired bacterial pneumonia pathogens","volume":"2","author":"T H Grossman","year":"2017","journal-title":"MSphere"},{"issue":"11","key":"ref147","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/13543784.2017.1385761","article-title":"Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia","volume":"26","author":"A Liapikou","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"06","key":"ref148","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1128\/AAC.01724-09","article-title":"Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila","volume":"54","author":"S Lemaire","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"ref149","doi-asserted-by":"crossref","first-page":"e01195-20","DOI":"10.1128\/AAC.01195-20","article-title":"In vitro activity and potency of the novel oxazolidinone contezolid (MRX-I) tested against gram-positive clinical isolates from the United States and Europe","volume":"64","author":"C G Carvalhaes","year":"2020","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1778641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:55:16Z","timestamp":1730804116000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1778641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":142,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2024,4,11]]},"published-print":{"date-parts":[[2024,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1778641","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}